Phaseline

Targets › METAP2

METAP2 (Methionine aminopeptidase 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). (UniProt, P50579)

Open in Phaseline: the race on METAP2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SynDevRxEvexomostat (SDX-7320)
MetAP2 inhibitor
METAP2Phase 1HR+/HER2-negative Breast CancerDec 2026

Conditions

HR+/HER2-negative Breast Cancer (1)

Modalities

small molecule (1)

Companies

SynDevRx (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.